Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome

Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome

US Patent 10261091 · Granted Apr 16, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Genetically modified natural killer cells for CD70-directed cancer immunotherapy2024
Gene expression markers for predicting overall survival in subjects treated with2024
Gene expression markers for predicting overall survival in subjects treated with2024
Gene expression markers for predicting overall survival in subjects treated with2024
Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immun2022
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2022
Cancer immunotherapy using CD19-directed chimeric antigen receptors2021
Immune cells engineered to express CD19-directed chimeric antigen receptors and 2021
Predictive modeling across multiple horizons combining time series and external 2020
Methods for inducing a natural killer (NK) cell-mediated immune response and for2013